Background: Curcumin (CUR), a bioactive compound with diverse therapeutic properties, faces challenges in clinical translation due to its poor aqueous solubility and low bioavailability. Nanosuspensions offer a promising strategy to enhance CUR's delivery and efficacy. Objective: This study aimed to formulate and characterize CUR nanosuspensions to improve its aqueous solubility and oral bioavailability. Methods: Various stabilizers were screened, and combination of PEG 400, Tween 80 and HPBCD was selected for its solubilizing capacity. The concentration of these stabilisers were optimized to enhance CUR solubility. Physicochemical properties, including particle size, polydispersity index (PDI), and zeta potential, were evaluated. Crystallinity was assessed using X-ray powder diffraction (XPRD) and differential scanning calorimetry (DSC). The drug content and in vitro drug release were determined. Furthermore, pharmacokinetic assessment was conducted in vivo to compare CUR nanosuspension with pure CUR. Results: The optimized CUR nanosuspension exhibited a particle size of 149 ± 7.2 nm, with a PDI of 0.276 ± 0.005 and a zeta potential of -9.49 ± 1.3 mV. XPRD and DSC confirmed the retention of CUR's crystalline structure. The nanosuspension displayed a high drug content (10% W/V) and significantly enhanced in vitro drug release compared to pure CUR. Pharmacokinetic assessment revealed prolonged systemic exposure and enhanced bioavailability of CUR nanosuspension compared to pure CUR. Conclusion: CUR nanosuspensions represent a promising approach to overcome the challenges associated with CUR's poor solubility and bioavailability. This study demonstrates the potential of nanosuspension technology to enhance drug delivery efficiency and efficacy, paving the way for improved clinical applications of CUR and other poorly water-soluble drugs